AS IV treatment inhibited the reduction in equol levels, suggesting that AS IV may inhibit GDM by modulating equol levels and improve insulin secretion failure through Chrebp/Txnip signaling by modulating PKA/PP2A signaling activity. The gene discussed is TXNIP; the disease is gestational diabetes.